Eddy,
not commenting on the effectiveness of CAR-T therapy, but i was listening to one of the aussie based CAR-T company men recently. The main hurdle as i see it with CAR-T is that they have to extract the patients blood and send it off to a very specific type of laboratory to tailor make the therapy according to each patients specific genetics/ blood make up ie each patient is different
Further to that he was stating that they were having good success with blood based cancers but having trouble with penetration into solid tumours
Those two factors seem like pretty decent barriers to a broadly successful drug and were the reason i stayed away from investing in the company
Ann: Expanded Heart Protection Discovery for Zantrene, page-272
-
- There are more pages in this discussion • 115 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.48 |
Change
-0.045(2.95%) |
Mkt cap ! $257.4M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.55 | $1.45 | $224.9K | 151.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 600 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 381 | 2 |
View Market Depth
| Last trade - 15.55pm 21/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |